SISB INVESTMENT ADVISERS (UK) LTD
Institutional investor · Portfolio as of Q1 2022
Top Holdings15 positions
Stock | Shares | Value | Weight | Avg Buy | Est. P&L | Held | Conviction |
|---|---|---|---|---|---|---|---|
COUPANG INC | 461.2M | $8.2B | 38.7% | $49.35 | -64.17% | 5 qtrssince 2021-Q1 | Decreased 0 |
DOORDASH INC - A | 33.6M | $3.9B | 18.7% | $140.20 | -15.67% | 6 qtrssince 2020-Q4 | Unchanged 0 |
GRAB HOLDINGS LTD - CL A | 699.2M | $2.4B | 11.6% | $7.15 | -50.35% | 2 qtrssince 2021-Q4 | Unchanged 0 |
UBER TECHNOLOGIES INC | 62.9M | $2.2B | 10.6% | $46.38 | -21.13% | 12 qtrssince 2019-Q2 | Decreased 0 |
COMPASS INC | 132.4M | $1B | 4.9% | $13.50 | -41.04% | 4 qtrssince 2021-Q2 | Unchanged 0 |
RELAY THERAPEUTICS INC | 27.9M | $835.2M | 4.0% | $39.98 | -23.31% | 7 qtrssince 2020-Q3 | Unchanged 0 |
VIR BIOTECHNOLOGY INC | 22.2M | $571.4M | 2.7% | $12.12 | +113.78% | 10 qtrssince 2019-Q4 | Unchanged 0 |
WEWORK INC | 81.1M | $553M | 2.6% | — | — | 2 qtrssince 2021-Q4 | Unchanged 0 |
ROIVANT SCIENCES LTD | 99.4M | $490.9M | 2.3% | $10.64 | -55.45% | 2 qtrssince 2021-Q4 | Unchanged 0 |
OPENDOOR TECHNOLOGIES INC | 41.4M | $358.3M | 1.7% | $24.27 | -62.34% | 6 qtrssince 2020-Q4 | Unchanged 0 |
AURORA INNOVATION INC | 39.4M | $220.3M | 1.0% | $11.41 | -48.64% | 2 qtrssince 2021-Q4 | Unchanged 0 |
VIEW INC | 66.2M | $121.8M | 0.6% | — | — | 5 qtrssince 2021-Q1 | Unchanged 0 |
ZYMERGEN INC | 26.6M | $76.9M | 0.4% | — | — | 4 qtrssince 2021-Q2 | Unchanged 0 |
Guardant Health, Inc. | 503,592 | $33.4M | 0.2% | $40.56 | +298.62% | 14 qtrssince 2018-Q4 | Unchanged 0 |
ONECONNECT FINL TECHNOLOGY C | 4.3M | $6.1M | 0.0% | — | — | — | — |
SB INVESTMENT ADVISERS (UK) LTD manages $21.1B across 15 positions as of Q1 2022. Top holdings: CPNG (38.7%), DASH (18.7%), GRAB (11.6%). Fund DNA: Concentrated Value. HoldingsIntel Rating: 2/5.0.
Trimmed 2. No standout high-conviction moves this quarter. Portfolio: $21.1B across 15 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
No active accumulation streaks detected for this filer.
Streaks require 2+ consecutive quarters of increased positions in the most recent period.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer